SEC Form 4 · accession 0000899243-16-012542
Clovis Oncology, Inc. · CLVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Corwin Dale Hooks
Officer — See Remarks
Period of report
Feb 1, 2016
Accepted (ET)
Feb 2, 2016 · 4:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001466301
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $20.90 | Feb 1, 2016 | A | 10,000 | A | — | Feb 1, 2026 | Common Stock | 10,000 | 10,000 | D |
| Stock option (right to buy)F2 | $20.90 | Feb 1, 2016 | A | 10,000 | A | — | Feb 1, 2026 | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1The option shall vest as to 25% of the shares on February 1, 2017, and the remainder shall vest in substantially equal installments over the 48 months immediately following such date.
- F2The option shall vest as to 50% of the shares on February 1, 2017, and the remainder shall vest on February 1, 2018.
Remarks
Senior Vice President and Chief Commercial Officer